Advent Life Sciences
Status
ACTIVE
Global HQ
Norwood, United States
Countries of investment
- USA
Investment stages
- Pre-Seed
- Seed
Industries
- Fintech
- Blockchain
- Crypto
- AI
- Data Services
About
Advent Life Sciences is a leading venture Capital firm based in London, United Kingdom and Massachusetts, United States. They have been investing in innovative life sciences companies since 2006. The companies in their portfolio have discovered and developed fourteen approved medicines and products, benefiting patients, physicians, and investors. The firm specializes in leading venture investments in the life sciences industry and has a highly experienced team with a longstanding track record of entrepreneurial and investment success. They work in close partnership with their portfolio companies and utilize a strong network to source the best opportunities and attract worldclass talent.
Advent Life Sciences is a leading venture Capital firm based in London, United Kingdom and Massachusetts, United States. They have been investing in innovative life sciences companies since 2006. The companies in their portfolio have discovered and developed fourteen approved medicines and products, benefiting patients, physicians, and investors. The firm specializes in leading venture investments in the life sciences industry and has a highly experienced team with a longstanding track record of entrepreneurial and investment success. They work in close partnership with their portfolio companies and utilize a strong network to source the best opportunities and attract worldclass talent.
Investment Thesis
Advent Life Sciences focuses on investing in innovative life sciences companies, leveraging their deep technical, commercial, and financial expertise to source the best opportunities and attract worldclass talent.
Portfolio
Levicept
Beacon Therapeutics
Amphista Therapeutics
Ventus Medical
Centessa Pharmaceuticals
AviadoBio
Almirall
Eloxx Pharmaceuticals
Argá Medtech
Curve Therapeutics
Aleta Biotherapeutics
Orphalan
Bayer
Aura Biosciences
Artax
Cancer Research UK
Bristol Myers Squibb